What it's for (Indications)
- Insulin degludec/liraglutide, marketed as Xultophy, is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus.
- This fixed-ratio combination product is typically considered for patients who have not achieved adequate glycemic control on a basal insulin regimen (less than 50 units daily) or on liraglutide (less than or equal to 1.
- 8 mg daily).
- It may also be used in patients who are uncontrolled on oral antidiabetic medications, or those already on either a basal insulin or a GLP-1 receptor agonist who require further intensification of therapy.
- The synergistic action of the two components addresses multiple pathophysiological defects of type 2 diabetes, offering comprehensive glucose lowering.
- It is crucial to emphasize that this medication is not indicated for the treatment of type 1 diabetes mellitus or for the management of diabetic ketoacidosis, as its mechanism of action is specifically tailored for the characteristics of type 2 diabetes.
- Furthermore, it has not been studied in combination with prandial insulin.
- Its use should be carefully considered within a comprehensive diabetes management plan that includes lifestyle modifications.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of insulin degludec/liraglutide is individualized based on the patient's clinical needs, glycemic control goals, and prior treatment history, with careful titration required to optimize efficacy while minimizing the risk of hypoglycemia. The starting dose is typically 16 units (16 units of insulin degludec and 0.6 mg of liraglutide), administered subcutaneously once daily. For patients previously on basal insulin, the starting dose should be based on their prior insulin dose, with careful consideration to avoid overtreatment. The dose should be titrated weekly or bi-weekly based on the patient’s fasting plasma glucose (FPG) levels, aiming for an FPG target as determined by the prescribing physician. The maximum recommended daily dose is 50 units (50 units of insulin degludec and 1.8 mg of liraglutide), as higher doses of liraglutide have not shown additional clinical benefit and may increase adverse effects. The injection should be administered at the same time each day, regardless of meal times. If a dose is missed, it should be taken as soon as possible, but no more than once a day. A double dose should not be taken to compensate for a missed dose. Dosing adjustments may be necessary in patients with renal or hepatic impairment and should be made with caution and close monitoring of blood glucose. |
Safety & Warnings
Common Side Effects
- Common adverse reactions associated with insulin degludec/liraglutide primarily include hypoglycemia, which is a known risk with insulin therapy, and gastrointestinal effects stemming from the liraglutide component.
- Gastrointestinal side effects often manifest as nausea, vomiting, diarrhea, and constipation, particularly during treatment initiation and dose titration.
- These symptoms are generally transient and tend to subside over time.
- Other reported side effects include headache, nasopharyngitis, and upper respiratory tract infection.
- More serious, albeit less common, adverse events include acute pancreatitis, which necessitates immediate discontinuation if suspected, and gallbladder-related disorders such as cholelithiasis and cholecystitis.
- Injection site reactions, such as pain, redness, or swelling, may also occur.
- There is also a potential for antibody formation, though the clinical significance of this is generally considered minimal.
- Patients should be educated on the signs and symptoms of hypoglycemia and severe gastrointestinal upset, and when to seek medical attention.
Serious Warnings
- Black Box Warning: WARNING: RISK OF THYROID C-CELL TUMORS. Liraglutide, one of the components of XULTOPHY 100/3.6, causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether XULTOPHY 100/3.6 causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined.
- Insulin degludec/liraglutide carries several important warnings and precautions.
- A prominent **Black Box Warning** exists for the liraglutide component, indicating a risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC).
- Therefore, this medication is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- The risk of acute pancreatitis is also a serious concern; patients should be advised of the symptoms (persistent severe abdominal pain, sometimes radiating to the back, with or without vomiting) and instructed to discontinue the medication and seek immediate medical attention if pancreatitis is suspected.
- Hypoglycemia is a significant risk, especially when co-administered with other insulin secretagogues or insulins, and requires careful glucose monitoring and dose adjustments.
- Due to potential gastrointestinal adverse reactions, patients are at risk for dehydration, which can lead to acute kidney injury, particularly in those with pre-existing renal impairment.
- This medication is not indicated for the treatment of diabetic ketoacidosis or type 1 diabetes.
- Serious hypersensitivity reactions (e.
- g.
- , anaphylaxis, angioedema) have been reported and require immediate discontinuation.
- Caution should be exercised in patients with a history of gallbladder disease.
- The safety and efficacy have not been established in pediatric patients, pregnant or lactating women.
How it Works (Mechanism of Action)
Insulin degludec/liraglutide is a co-formulation providing complementary glycemic control mechanisms. **Insulin degludec** is a basal insulin analog characterized by its ultra-long duration of action. Following subcutaneous injection, it forms soluble multi-hexamers, creating a depot from which insulin degludec is slowly and continuously released into the circulation. This prolonged absorption profile results in a stable, protracted glucose-lowering effect lasting over 42 hours. Insulin degludec primarily reduces hepatic glucose production and enhances peripheral glucose uptake into muscle and fat cells. **Liraglutide** is a glucagon-like peptide-1 (GLP-1) receptor agonist, which works via several glucose-dependent mechanisms. It binds to and activates GLP-1 receptors, leading to increased glucose-dependent insulin secretion from pancreatic beta cells, thereby lowering postprandial glucose levels. Concurrently, it suppresses inappropriately elevated glucagon secretion from pancreatic alpha cells, further contributing to reduced hepatic glucose output. Liraglutide also slows gastric emptying, which helps to mitigate postprandial glucose excursions, and it has central effects that promote satiety, potentially leading to reduced caloric intake and weight loss. The combined action of these two agents provides comprehensive glycemic control by addressing both fasting and postprandial glucose levels through distinct yet synergistic pathways.
Commercial Brands (Alternatives)
No other brands found for this formula.